Trevi Therapeutics is lining up a concentrated May roadshow around Haduvio, its oral extended-release nalbuphine for chronic cough, with an Investor and Analyst Day in New York on May 7, a corporate slot at the Bank of America Global Healthcare Conference on May 12, and an in-person investor session highlighting new data alongside the ATS 2026 International Conference on May 18. The cadence suggests a coordinated bid to frame the scientific and commercial narrative ahead of a potentially pivotal period for cough therapeutics, spanning idiopathic pulmonary fibrosis and other interstitial lung diseases as well as refractory chronic cough.
The strategic question is whether Trevi can convert clinical signal into category leadership in a market where the regulatory bar remains fluid and the competitive field is regrouping. By orchestrating KOL-heavy touchpoints around ATS and courting the generalist investor audience in the same fortnight, the company is telegraphing confidence that its kappa agonist/mu antagonist mechanism can stand apart from the dominant P2X3 antagonist class and that the breadth across IPF/ILD cough and RCC is an asset rather than a distraction.
This matters because the clinical and economic burden is substantial and still largely unaddressed. In the United States, approximately 140,000 patients live with IPF and about two-thirds suffer uncontrolled chronic cough; a further 228,000 patients have non-IPF ILD, with 50–60% affected by cough. These patients can cough up to 1,500 times per day, with downstream risks that include disease worsening, higher progression rates, respiratory hospitalizations, and profound quality-of-life decline. RCC adds another two to three million patients, a heterogeneous population defined by persistent cough despite guideline-directed management of underlying conditions. For pulmonologists and allergists, a therapy that modulates both central and peripheral aspects of the cough reflex would represent a new tool, but it will require rigorous education on mechanism, benefit-risk, and use alongside antifibrotics or other standard therapies. For payers, reductions in objective cough frequency will need to connect to patient-relevant outcomes, healthcare utilization, and productivity to justify coverage in both orphan-like ILD segments and the broader RCC market. The fact that nalbuphine is not a DEA-scheduled drug may ease some access and prescribing friction, though perceptions around opioid pharmacology will still need careful Medical Affairs stewardship.
The broader industry context is shifting. Chronic cough has attracted renewed big pharma interest, but U.S. regulators have pushed back on past filings, underscoring uncertainty around acceptable endpoints and the magnitude of clinical benefit required. Meanwhile, class-defining P2X3 antagonists have faced tolerability trade-offs that leave room for differentiated mechanisms. Trevi’s claim of statistically significant cough frequency reductions in both IPF-related cough and RCC positions Haduvio as a mechanistically distinct challenger in a field searching for durable, tolerable solutions. The timing of investor engagement around ATS fits a well-worn biotech playbook: amplify scientific data to catalyze business development conversations or set the stage for future financing.
Commercial and Medical Affairs leaders should prepare for a bifurcated path if the upcoming readouts hold. In ILD-related cough, a specialty-driven strategy anchored in pulmonology centers of excellence, real-world evidence on exacerbations and hospitalizations, and nuanced safety communication could support premium positioning. In RCC, scale will hinge on digital cough monitoring adoption, alignment on clinically meaningful thresholds, and early dialogue with payers to define step-throughs and patient selection. Competitors will interrogate cross-trial comparability, durability of effect, and tolerability; Trevi will need to show not only fewer coughs, but better lives and lower costs.
The next hinge question is whether May’s data and engagements can translate into regulatory clarity and partnership momentum that de-risk late-stage development. If Haduvio can deliver consistent, clinically meaningful benefit across both specialty ILD cough and mass-market RCC, the cough category may be set for diversification beyond a single mechanism—otherwise, consolidation around one dominant class could resume quickly.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
